This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yaguchi, M., Miyazawa, K., Otawa, M. et al. Vitamin K2 therapy for a patient with myelodysplastic syndrome. Leukemia 13, 144–145 (1999). https://doi.org/10.1038/sj.leu.2401232
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401232
This article is cited by
-
Synergistic growth inhibition in HL-60 cells by the combination of acyclic retinoid and vitamin K2
Journal of Cancer Research and Clinical Oncology (2011)
-
Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells
Leukemia (2001)
-
Vitamin K2 therapy for myelodysplastic syndromes (MDS) and post-MDS acute myeloid leukemia: information through a questionnaire survey of multi-center pilot studies in Japan
Leukemia (2000)